Financials / Press Releases

INVESTOR RELATIONS

BIOQUAL, Inc. is a public company traded on the OTC Markets Group – Symbol BIOQ.

BIOQUAL, Inc.’s Transfer Agent:

Computershare, Inc.
480 Washington Boulevard
Jersey City, New Jersey 07310
www.computershare.com

Contact Us

CONTACT:

Mark Lewis
President / Chief Executive Officer
BIOQUAL, Inc.
Phone: (240) 404-7654

Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques

Host immunity associated with spontaneous suppression of viremia in therapy-nave young rhesus macaques following neonatal SHIV infection

BIOQUAL Presents Unaudited Financial Results and Managements Discussion and Analysis for FY 2024 First Quarter Ending August 31, 2023

BIOQUAL congratulates Drew Weissman and Katalin Kariko on receiving the 2023 Nobel Prize in Medicine. We are pleased to have played a part in extending their early findings to preclinical testing of the mRNA platform

BIOQUAL Dividend News Release FY23

BIOQUAL Presents Audited Financial Statements for FY 2023

Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates

Investigation of the impact of clonal hematopoiesis on severity and pathophysiology of COVID-19 in rhesus macaques

Bioqual Dividend News Release FY23

BIOQUAL Presents Unaudited Financial Results and Managements Discussion and Analysis for FY 2024 Second Quarter Ending November 30, 2023

 

BIOQUAL Presents Unaudited Financial Results and Managements Discussion and Analysis for FY 2024 First Quarter Ending August 31, 2023

 

BIOQUAL Dividend News Release FY23

 

BIOQUAL Presents Audited Financial Statements for FY 2023

 

BIOQUAL Presents Unaudited Financial Results and Managements Discussion and Analysis for FY 2023 Third Quarter Ending February 28, 2023

 

BIOQUAL Presents Unaudited Financial Results and Managements Discussion and Analysis for FY 2023 Second Quarter Ending November 30, 2022

 

BIOQUAL Announces Results from 2022 Meeting of Stockholders [Updated 10/28/22]

 

BIOQUAL Presents Unaudited Financial Results and Managements Discussion and Analysis for FY 2023 First Quarter Ending August 31, 2022

Press Release C. Kirk Appointment as CFO

 

BIOQUAL Dividend News Release 9-27-2

 

BIOQUAL Presents Audited Financial Statements for Fiscal Year 2022

 

Press Release, BIOQUAL, Inc. Announces Publication of Pan-Coronavirus Vaccine Study [Updated 07/06/22]

 

Press Release, BIOQUAL, Inc. Announces Creation of the Role of Chief Scientific Officer and Appointment of Hanne Andersen Elyard, PhD, as the initial Chief Scientific Officer [Updated 05/09/22]

 

Press Release, BIOQUAL, Inc. Announces that Dave Newcomer Will Retire from His Role as Chief Financial Officer and Has Been Unanimously Appointed to Fill a Vacant Seat on the Board of Directors at BIOQUAL [05/09/22]

 

BIOQUAL Presents Unaudited Financial Results and Management’s Discussion and Analysis for FY 2022 Third Quarter Ending February 28, 2022 [Updated 04/21/22]

 

Press Release, BIOQUAL, Inc. Presents Financial Results for FY 2022 Third Quarter [Updated 04/21/22]

 

Press Release, 02/18/22, BIAL Award in Biomedicine distinguishes research which is the basis of two of the vaccines against COVID-19

 

BIOQUAL Presents Financial Results for FY 2022 Second Quarter Ending November 30, 2021 [Updated 01/21/22]

 

Press Release, 01/21/22, BIOQUAL, Inc. and Subsidiary Presents Financial Results for Second Quarter of Fiscal Year 2022

 

BIOQUAL Announces Results from 2021 Meeting of Stockholders [Updated 10/29/21]

 

BIOQUAL Presents Unaudited Financial Statements and Management’s Discussion and Analysis for the Quarterly Period ending August 31, 2021 [Updated 10/22/21]

 

Press Release, BIOQUAL, Inc. Announces Unaudited Financial Results for FY 2022 1st Quarter [10/22/21]

 

Management’s Discussion and Analysis Related to the Audited Financial Statements for Fiscal Year 2021 [Updated 09/17/21]

 

BIOQUAL, Inc. and Subsidiary Presents Audited Consolidated Financial Statements for Fiscal Year 2021 [Updated 09/17/21]

 

Press Release, 09/17/21, BIOQUAL, Inc. and Subsidiary Presents Financial Results for Fiscal Year 2021 and Declares Dividend

 

Press Release, 01/22/21, John C. Landon, founder of BIOQUAL, Inc., passes away at the age of 84

 

Press Release, 09/21/20, BIOQUAL, Inc. and Subsidiary Announces Publication of an Investigational COVID-19 Vaccine Candidate that Prevents Severe Clinical Disease in Animals

 

 Management’s Discussion and Analysis Related to the Audited Financial Statements for Fiscal Year 2020 [Updated 09/14/20]

 

 BIOQUAL, Inc. and Subsidiary Presents Audited Consolidated Financial Statements for Fiscal Year 2020 [Updated 09/14/20]

 

 Press Release, 09/15/20, BIOQUAL, Inc. and Subsidiary Presents Financial Results for Fiscal Year 2020 and Declares Dividend

 

 BIOQUAL Announces Publication New England Journal Medicine. August, 10, 2020

 

 Press Release, BIOQUAL, Inc. July 31, 2020 Rockville

 

 Press Release, BIOQUAL, Inc. Announces Release of Two COVID-19 Research Publications [05/20/20]

 

 Press Release, 04/07/20, Scheduling of Annual Shareholder Meeting

 

 Press Release, 03/31/20, BIOQUAL Announces COVID-19 Vaccine Testing

 

 Mark Lewis Letter To Shareholders [09/20/19]

 

 Management’s Discussion and Analysis Related to the Audited Financial Statements for Fiscal Year 2019 [Updated 09/13/19]

 

 BIOQUAL, Inc. and Subsidiary Presents Audited Consolidated Financial Statements for Fiscal Year 2019 [Updated 09/13/19]

 

 Press Release, 09/13/19, BIOQUAL, Inc. and Subsidiary Presents Financial Results for Fiscal Year 2019 and Declares Dividend

 

 In Memoriam, J. Thomas August, M.D. [Updated 02/22/19]

 

 Press Release, 02/22/19, Death of J. Thomas August, M.D., a Member of the Board of Directors of BIOQUAL, Inc.

 

 Mark Lewis Letter To Shareholders [10/18/18]

 

 Press Release, 09/11/18, BIOQUAL, Inc. and Subsidiary Presents Financial Results for Fiscal Year 2018 and Declares Dividend

 

 BIOQUAL, Inc. and Subsidiary Presents Audited Financial Statements ending May 31, 2018 and 2017 [Updated 09/11/18]

Please send mail to itdept@bioqual.com with questions or comments about this website.